A Phase 2/3 interventional study of Imatinib mesylate and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 4th largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
STI571
Drug: Imatinib mesylate
Placebo
Drug: Placebo
Open label extension
Drug: Imatinib mesylate
Also known as: Imatinib, Glivec, Gleevec, STI571, QTI571
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Time frame: 6 months
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Time frame: 72 months
Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Number of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity
PAH assessed according to the WHO classification: Class I Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion
Borg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. The test was terminated if the patient became too distressed or if their SaO2% fell below 60%.
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Systolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Diastolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Heart Rate (bpm) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score During the Six Minutes Walk Test at Different Time Periods
Borg Score during Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Borg Score of Breathlessness was recorded using the following score of 0 to 10, how breathless do you feel? 0 is nothing at all and 10 is maximal breathlessness
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Mean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including right Pulmonary Arterial Pressure (PAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Time frame: Baseline, and Study completion (Week 24)
Mean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Arterial Wedge Pressure (PAWP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Time frame: Baseline, and Study completion (Week 24)
Mean Systolic Arterial Pressure (SAP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systolic Arterial Pressure (SAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Time frame: Baseline, and Study completion (Week 24)
Mean Heart Rate (HR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Heart Rate (HR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Time frame: Baseline, and Study completion (Week 24)
Mean Cardiac Output (CO) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Cardiac Output (CO). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Time frame: Baseline, and Study completion (Week 24)
Mean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. PVR calculated according to the equation:PVR = (PAP - PCWP)/CO
Time frame: Baseline, and Study completion (Week 24)
Mean Systemic Vascular Resistance (SVR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systemic Vascular Resistance (SVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. SVR was calculated according to the equation: SVR = (Paorta - Pright atrium)/CO
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaO2 levels at baseline and Study completion Week 24.
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaCO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaCO2 levels at baseline and Study completion Week 24.
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PvO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PvO2 levels at baseline and Study completion Week 24.
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Arterial Saturation at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Arterial Saturation levels at baseline and Study completion Week 24.
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Venous Saturation at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Venous Saturation levels at baseline and Study completion Week 24.
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - pH at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including pH levels at baseline and Study completion Week 24. The pH scale measures how acidic or basic a substance is. It ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic.
Time frame: Baseline, and Study completion (Week 24)
Of the 42 participants that completed the Core Study only 22 Participants continued into the Open Label Extension. Not all participants were required to continue into the extension from the core.
| Milestone | STI571 | Placebo | All Patients |
|---|---|---|---|
| Started | 28 | 31 | 0 |
| Completed | 19 | 23 | 0 |
| Not completed | 9 | 8 | 0 |
| Withdrew: Adverse event | 6 | 4 | 0 |
| Withdrew: Death | 3 | 3 | 0 |
| Withdrew: Withdrawn consent | 0 | 1 | 0 |
| Milestone | STI571 | Placebo | All Patients |
|---|---|---|---|
| Started | 0 | 0 | 22 |
| Completed | 0 | 0 | 9 |
| Not completed | 0 | 0 | 13 |
| Withdrew: Adverse event | 0 | 0 | 4 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effects | 0 | 0 | 2 |
| Withdrew: Adminiatrative problems | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 4 |
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
| participants | STI571 | Placebo |
|---|---|---|
| Paients with AE(s) | 27 | 29 |
| Death | 3 | 3 |
| SAE(s) | 12 | 11 |
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
| participants | All Patients |
|---|---|
| Any AE(s) | 22 |
| Death | 4 |
| SAE(s) | 16 |
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.
| meters | STI571 | Placebo |
|---|---|---|
| Day 32 (n=25,27) | 10.2 ± 53.7 | 8.2 ± 27.5 |
| week 8 (n=23,24) | 17.0 ± 55.6 | 15.5 ± 40.8 |
| week 12 (n=22,24) | 21 ± 36.2 | 7.8 ± 50.0 |
| week 16 (n=19, 23) | 25.5 ± 43.1 | 12.1 ± 47.9 |
| week 20 (n=19, 21) | 38.3 ± 42.5 | 12.8 ± 60.4 |
| study completion Week 24 (n=21, 12) | 22.0 ± 63.1 | -1.0 ± 53.3 |
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.
| number of stops | STI571 | Placebo |
|---|---|---|
| Day 32 (n=25,27) | -0.2 ± 0.7 | 0.1 ± 0.4 |
| week 8 (n=23,24) | -0.2 ± 0.7 | 0.0 ± 1.1 |
| week 12 (n=22,24) | -0.3 ± 0.9 | 0.3 ± 0.9 |
| week 16 (n=19, 23) | -0.3 ± 0.8 | 0.0 ± 0.2 |
| week 20 (n=19, 21) | -0.4 ± 1.0 | 0.3 ± 1.0 |
| study completion Week 24 (n=21, 12) | -0.3 ± 0.8 | -0.1 ± 0.5 |
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.
| minutes | STI571 | Placebo |
|---|---|---|
| Day 32 (n=25,27) | -0.06 ± 0.19 | 0.12 ± 0.36 |
| week 8 (n=23,24) | -0.03 ± 0.10 | 0.07 ± 0.27 |
| week 12 (n=22,24) | -0.03 ± 0.10 | 0.19 ± 0.55 |
| week 16 (n=19, 23) | -0.03 ± 0.10 | 0.06 ± 0.26 |
| week 20 (n=19, 21) | -0.05 ± 0.15 | 0.12 ± 0.42 |
| study completion Week 24 (n=21, 12) | -0.02 ± 0.10 | 0.03 ± 0.18 |
PAH assessed according to the WHO classification: Class I Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
| number of participants | STI571 | Placebo |
|---|---|---|
| Baseline: WHO Class IV (n=27,30) | 2 | 1 |
| Baseline: WHO Class III (n=27,30) | 14 | 22 |
| Baseline: WHO Class II (n=27,30) | 11 | 7 |
| Day 32: WHO Class IV (n=27,30) | 3 | 3 |
| Day 32: WHO Class III (n=27,30) | 11 | 21 |
| Day 32: WHO Class II (n=27,30) | 13 | 6 |
| Week 8: WHO Class IV (n=24,27) | 3 | 1 |
| Week 8: WHO Class III (n=24,27) | 9 | 20 |
| Week 8: WHO Class II (n=24,27) | 12 | 6 |
| Week 12: WHO Class IV (n=23,27) | 0 | 1 |
| Week 12: WHO Class III (n=23,27) | 12 | 17 |
| Week 12: WHO Class II (n=23,27) | 11 | 9 |
| Week 16: WHO Class IV (n=22,27) | 0 | 1 |
| Week 16: WHO Class III (n=22,27) | 11 | 18 |
| Week 16: WHO Class II (n=22,27) | 11 | 7 |
| Week 16: WHO Class I (n=22,27) | 0 | 1 |
| Week 20: WHO Class IV (n=19,24) | 0 | 1 |
| Week 20: WHO Class III (n=19,24) | 10 | 14 |
| Week 20: WHO Class II (n=19,24) | 8 | 9 |
| Week 20: WHO Class I (n=19,24) | 1 | 0 |
| Week 24: WHO Class IV (n=21,25) | 1 | 2 |
| Week 24: WHO Class III (n=21,25) | 12 | 13 |
| Week 24: WHO Class II (n=21,25) | 8 | 10 |
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. The test was terminated if the patient became too distressed or if their SaO2% fell below 60%.
| Percentage of Oxygen Saturation | STI571 | Placebo |
|---|---|---|
| Baseline: Resting (n= 28, 29) | 94.3 ± 4.6 | 93.4 ± 4.7 |
| Baseline: End of Test (n= 28, 28) | 87.9 ± 12.4 | 87.9 ± 8.2 |
| Baseline: 2 minutes after end of test (n=26, 26) | 93.0 ± 7.0 | 92.0 ± 6.2 |
| Day 32: Resting (n= 25, 28) | 94.5 ± 4.0 | 92.4 ± 6.3 |
| Day 32: End of Test (n= 25, 28) | 89.0 ± 11.2 | 87.2 ± 12.8 |
| Day 32: 2 minutes after end of test (n= 25, 26) | 94.8 ± 4.6 | 92.7 ± 7.1 |
| Week 8: Resting (n= 23, 25) | 95.1 ± 3.3 | 93.2 ± 6.1 |
| Week 8: End of Test (n= 23, 24) | 90.9 ± 6.7 | 87.9 ± 11.9 |
| Week 8: 2 minutes after end of test (n= 23, 23) | 94.4 ± 5.3 | 93.1 ± 7.8 |
| Week 12: Resting (n= 22, 25) | 95.1 ± 4.8 | 93.9 ± 5.6 |
| Week 12: End of Test (n= 20, 24) | 89.8 ± 9.2 | 89.6 ± 8.9 |
| Week 12: 2 minutes after end of test (n= 19, 22) | 92.7 ± 8.9 | 94.2 ± 5.6 |
| Week 16: Resting (n= 19, 24) | 95.0 ± 5.0 | 94.1 ± 5.1 |
| Week 16: End of Test (n= 18, 23) | 87.9 ± 13.1 | 88.1 ± 9.8 |
| Week 16: 2 minutes after end of test (n= 19, 19) | 94.6 ± 6.0 | 93.3 ± 8.0 |
| Week 20: Resting (n= 19, 22) | 94.0 ± 4.7 | 93.7 ± 5.0 |
| Week 20: End of Test (n= 18, 21) | 87.5 ± 13.2 | 87.6 ± 9.1 |
| Week 20: 2 minutes after end of test (n= 19, 21) | 93.8 ± 7.1 | 93.4 ± 7.4 |
| Week 24: Resting (n= 20, 22) | 95.5 ± 3.4 | 94.3 ± 4.6 |
| Week 24: End of Test (n= 20, 21) | 89.9 ± 7.1 | 89.3 ± 8.4 |
| Week 24: 2 minutes after end of test (n= 20, 21) | 94.8 ± 4.3 | 94.8 ± 3.9 |
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Systolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline: Resting (n= 26, 28) | 111.3 ± 14.2 | 104.6 ± 13.2 |
| Baseline: End of Test (n= 21, 26) | 119.9 ± 19.3 | 118.3 ± 18.0 |
| Baseline: 2 minutes after end of test (n=25, 27) | 120.0 ± 18.3 | 110.4 ± 13.6 |
| Day 32: Resting (n= 25, 27) | 111.4 ± 9.6 | 106.0 ± 12.3 |
| Day 32: End of Test (n= 22, 22) | 126.5 ± 17.3 | 122.3 ± 18.6 |
| Day 32: 2 minutes after end of test (n= 25, 26) | 119.6 ± 12.6 | 113.8 ± 14.9 |
| Week 8: Resting (n= 22, 24) | 108.9 ± 12.3 | 107.3 ± 13.5 |
| Week 8: End of Test (n= 19, 20) | 124.6 ± 16.1 | 119.9 ± 17.1 |
| Week 8: 2 minutes after end of test (n= 23, 24) | 115.2 ± 13.6 | 114.5 ± 13.7 |
| Week 12: Resting (n= 22, 23) | 106.5 ± 11.5 | 107.7 ± 13.8 |
| Week 12: End of Test (n= 17, 19) | 122.2 ± 17.0 | 118.8 ± 22.9 |
| Week 12: 2 minutes after end of test (n= 20, 22) | 115.9 ± 14.2 | 115.9 ± 14.9 |
| Week 16: Resting (n= 19, 22) | 106.7 ± 9.7 | 105.7 ± 12.5 |
| Week 16: End of Test (n= 15,18) | 117.2 ± 12.3 | 119.8 ± 13.5 |
| Week 16: 2 minutes after end of test (n= 19, 22) | 114.6 ± 13.8 | 112.6 ± 15.8 |
| Week 20: Resting (n= 19, 20) | 106.5 ± 7.0 | 109.1 ± 12.1 |
| Week 20: End of Test (n= 16,17) | 122.4 ± 13.3 | 119.9 ± 19.3 |
| Week 20: 2 minutes after end of test (n= 19, 20) | 115.5 ± 14.0 | 115.1 ± 15.1 |
| Week 24: Resting (n= 20, 21) | 110.6 ± 15.6 | 108.2 ± 15.7 |
| Week 24: End of Test (n= 16, 17) | 126.9 ± 23.6 | 116.8 ± 14.9 |
| Week 24: 2 minutes after end of test (n= 20, 19) | 118.2 ± 18.6 | 111.1 ± 10.6 |
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Diastolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline: Resting (n= 26, 28) | 68.2 ± 10.2 | 67.9 ± 8.9 |
| Baseline: End of Test (n= 21, 26) | 75.1 ± 10.8 | 69.5 ± 11.9 |
| Baseline: 2 minutes after end of test (n=25, 27) | 71.6 ± 9.8 | 67.9 ± 9.6 |
| Day 32: Resting (n= 25, 27) | 69.6 ± 10.4 | 68.4 ± 8.8 |
| Day 32: End of Test (n= 22, 22) | 78.2 ± 12.3 | 75.2 ± 11.2 |
| Day 32: 2 minutes after end of test (n= 25, 26) | 72.5 ± 9.1 | 70.7 ± 9.4 |
| Week 8: Resting (n= 22, 24) | 67.7 ± 11.8 | 68.8 ± 9.0 |
| Week 8: End of Test (n= 19, 20) | 74.8 ± 10.8 | 74.0 ± 10.9 |
| Week 8: 2 minutes after end of test (n= 23, 24) | 71.2 ± 10.3 | 72.2 ± 11.7 |
| Week 12: Resting (n= 22, 23) | 65.5 ± 8.3 | 70.6 ± 11.6 |
| Week 12: End of Test (n= 17, 19) | 75.6 ± 11.5 | 72.4 ± 14.3 |
| Week 12: 2 minutes after end of test (n= 20, 22) | 73.1 ± 8.9 | 72.0 ± 13.7 |
| Week 16: Resting (n= 19, 22) | 67.7 ± 9.9 | 66.7 ± 7.7 |
| Week 16: End of Test (n= 15,18) | 72.7 ± 9.2 | 76.7 ± 8.6 |
| Week 16: 2 minutes after end of test (n= 19, 22) | 71.4 ± 11.0 | 70.5 ± 8.0 |
| Week 20: Resting (n= 19, 20) | 67.2 ± 8.0 | 69.8 ± 8.8 |
| Week 20: End of Test (n= 16,17) | 72.9 ± 8.7 | 72.9 ± 8.1 |
| Week 20: 2 minutes after end of test (n= 19, 20) | 71.9 ± 9.2 | 72.7 ± 9.8 |
| Week 24: Resting (n= 20, 21) | 69.7 ± 10.3 | 70.7 ± 10.9 |
| Week 24: End of Test (n= 16, 17) | 74.1 ± 10.7 | 72.3 ± 10.9 |
| Week 24: 2 minutes after end of test (n= 20, 19) | 71.3 ± 10.1 | 72.9 ± 9.5 |
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Heart Rate (bpm) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
| beats per minute (bpm) | STI571 | Placebo |
|---|---|---|
| Baseline: Resting (n= 28, 29) | 80.8 ± 13.0 | 87.9 ± 12.7 |
| Baseline: End of Test (n= 28, 29) | 106.3 ± 23.9 | 112.3 ± 20.4 |
| Baseline: 2 minutes after end of test (n=26, 26) | 84.2 ± 16.9 | 94.1 ± 14.6 |
| Day 32: Resting (n= 25, 28) | 80.7 ± 14.3 | 83.6 ± 15.7 |
| Day 32: End of Test (n= 25, 28) | 108.4 ± 19.1 | 113.1 ± 19.5 |
| Day 32: 2 minutes after end of test (n= 25, 26) | 89.2 ± 17.0 | 90.6 ± 14.1 |
| Week 8: Resting (n= 23, 25) | 80.3 ± 9.6 | 81.1 ± 11.2 |
| Week 8: End of Test (n= 23, 24) | 109.5 ± 21.4 | 110.3 ± 26.4 |
| Week 8: 2 minutes after end of test (n= 23, 23) | 85.3 ± 15.7 | 88.9 ± 13.2 |
| Week 12: Resting (n= 22, 25) | 76.5 ± 13.2 | 85.1 ± 13.2 |
| Week 12: End of Test (n= 20, 25) | 105.3 ± 26.2 | 113.0 ± 26.5 |
| Week 12: 2 minutes after end of test (n= 19, 22) | 83.8 ± 17.8 | 89.4 ± 15.7 |
| Week 16: Resting (n= 19, 24) | 76.5 ± 13.2 | 84.4 ± 12.9 |
| Week 16: End of Test (n= 18, 23) | 102.8 ± 25.6 | 117.9 ± 24.3 |
| Week 16: 2 minutes after end of test (n= 19, 21) | 85.8 ± 21.0 | 85.5 ± 14.4 |
| Week 20: Resting (n= 19, 22) | 75.3 ± 13.8 | 80.2 ± 9.6 |
| Week 20: End of Test (n= 18,22) | 109.2 ± 26.8 | 118.0 ± 24.5 |
| Week 20: 2 minutes after end of test (n= 19, 21) | 83.3 ± 17.4 | 87.3 ± 11.4 |
| Week 24: Resting (n= 20, 22) | 79.5 ± 13.8 | 83.6 ± 8.6 |
| Week 24: End of Test (n= 20, 21) | 110.2 ± 18.1 | 116.8 ± 21.7 |
| Week 24: 2 minutes after end of test (n= 20, 21) | 87.9 ± 17.5 | 88.9 ± 11.8 |
Borg Score during Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Borg Score of Breathlessness was recorded using the following score of 0 to 10, how breathless do you feel? 0 is nothing at all and 10 is maximal breathlessness
| score on a scale | STI571 | Placebo |
|---|---|---|
| Baseline: Resting (n= 26, 27) | 0.27 ± 0.83 | 0.43 ± 0.92 |
| Baseline: End of Test (n= 27, 29) | 3.34 ± 2.30 | 3.02 ± 1.59 |
| Baseline: 2 minutes after end of test (n=24, 26) | 0.88 ± 1.67 | 1.08 ± 1.47 |
| Day 32: Resting (n= 25, 27) | 0.24 ± 0.83 | 0.48 ± 0.86 |
| Day 32: End of Test (n= 25, 28) | 2.53 ± 2.02 | 3.07 ± 2.08 |
| Day 32: 2 minutes after end of test (n= 25, 26) | 0.65 ± 2.06 | 1.06 ± 1.34 |
| Week 8: Resting (n= 23, 24) | 0.32 ± 1.02 | 0.38 ± 0.81 |
| Week 8: End of Test (n= 23, 25) | 2.46 ± 2.02 | 2.32 ± 1.64 |
| Week 8: 2 minutes after end of test (n= 23, 24) | 0.32 ± 0.92 | 0.58 ± 1.04 |
| Week 12: Resting (n= 22, 24) | 0.05 ± 0.21 | 0.46 ± 0.97 |
| Week 12: End of Test (n= 22, 25) | 2.27 ± 1.59 | 2.92 ± 1.95 |
| Week 12: 2 minutes after end of test (n= 22, 23) | 0.35 ± 0.68 | 0.65 ± 1.06 |
| Week 16: Resting (n= 19, 23) | 0.13 ± 0.33 | 0.50 ± 1.23 |
| Week 16: End of Test (n= 18, 23) | 2.50 ± 1.91 | 2.83 ± 1.69 |
| Week 16: 2 minutes after end of test (n= 19, 23) | 0.41 ± 0.72 | 0.70 ± 1.25 |
| Week 20: Resting (n= 19, 21) | 0.05 ± 0.16 | 0.67 ± 1.14 |
| Week 20: End of Test (n= 18,22) | 2.31 ± 1.70 | 3.11 ± 2.17 |
| Week 20: 2 minutes after end of test (n= 18, 20) | 0.31 ± 0.55 | 0.75 ± 1.15 |
| Week 24: Resting (n= 20, 21) | 0.18 ± 0.49 | 0.40 ± 0.82 |
| Week 24: End of Test (n= 20, 21) | 2.58 ± 1.87 | 2.93 ± 1.90 |
| Week 24: 2 minutes after end of test (n= 20, 20) | 0.29 ± 0.62 | 0.67 ± 1.07 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including right Pulmonary Arterial Pressure (PAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=27,28) | 61.7 ± 15.6 | 59.2 ± 11.6 |
| Baseline every 2 mins breathing NO (1st) (n=20,20) | 61.6 ± 18.7 | 55.7 ± 12.0 |
| Baseline every 2 mins breathing NO (2nd) (n=17,18) | 58.1 ± 16.7 | 53.3 ± 11.5 |
| Baseline 5 mins after NO administration (n=20,14) | 60.9 ± 16.2 | 56.9 ± 10.8 |
| Baseline 15 mins after NO administration(n=19,19) | 60.3 ± 16.0 | 56.5 ± 10.3 |
| Week 24 breathing ambient air (n=20,22) | 52.5 ± 11.4 | 55.5 ± 11.6 |
| Week 24 every 2 mins breathing NO (1st) (n=10,13) | 50.9 ± 17.5 | 55.1 ± 13.9 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 46.2 ± 18.1 | 53.9 ± 14.1 |
| Week 24 5 mins after NO administration (n=10,12) | 47.0 ± 15.8 | 57.5 ± 12.8 |
| Week 24 15 mins after NO administration (n=10,14) | 48.1 ± 13.7 | 57.2 ± 12.4 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Arterial Wedge Pressure (PAWP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=26,28) | 9.0 ± 2.6 | 7.6 ± 2.3 |
| Baseline every 2 mins breathing NO (1st) (n=20,17) | 9.5 ± 2.0 | 7.7 ± 2.9 |
| Baseline every 2 mins breathing NO (2nd) (n=17,16) | 9.4 ± 2.2 | 7.8 ± 3.4 |
| Baseline 5 mins after NO administration (n=19,12) | 9.5 ± 2.7 | 7.8 ± 2.9 |
| Baseline 15 mins after NO administration(n=18,17) | 9.6 ± 2.4 | 8.1 ± 2.6 |
| Week 24 breathing ambient air (n=19,22) | 8.4 ± 3.2 | 8.6 ± 2.8 |
| Week 24 every 2 mins breathing NO (1st) (n=9,13) | 7.9 ± 3.1 | 10.2 ± 3.7 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 7.0 ± 3.4 | 10.0 ± 3.7 |
| Week 24 5 mins after NO administration (n=10,12) | 7.1 ± 3.1 | 10.3 ± 3.3 |
| Week 24 15 mins after NO administration (n=10,14) | 6.7 ± 2.8 | 10.4 ± 3.6 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systolic Arterial Pressure (SAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=26,28) | 110.3 ± 19.5 | 108.2 ± 15.4 |
| Baseline every 2 mins breathing NO (1st) (n=20,19) | 108.3 ± 18.9 | 106.9 ± 18.0 |
| Baseline every 2 mins breathing NO (2nd) (n=17,17) | 109.9 ± 19.1 | 105.4 ± 18.1 |
| Baseline 5 mins after NO administration (n=21,15) | 106.0 ± 17.7 | 107.1 ± 18.6 |
| Baseline 15 mins after NO administration(n=19,19) | 109.5 ± 20.3 | 106.9 ± 16.7 |
| Week 24 breathing ambient air (n=20,22) | 108.0 ± 19.8 | 106.9 ± 18.8 |
| Week 24 every 2 mins breathing NO (1st) (n=10,13) | 103.9 ± 17.5 | 102.9 ± 20.4 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 104.8 ± 18.3 | 103.6 ± 19.2 |
| Week 24 5 mins after NO administration (n=9,12) | 103.4 ± 18.7 | 104.0 ± 20.0 |
| Week 24 15 mins after NO administration (n=10,14) | 103.8 ± 21.4 | 107.3 ± 18.3 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Heart Rate (HR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
| beats per minute (bpm) | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=27,28) | 77.3 ± 7.5 | 84.9 ± 13.0 |
| Baseline every 2 mins breathing NO (1st) (n=20,19) | 75.9 ± 12.9 | 84.4 ± 15.5 |
| Baseline every 2 mins breathing NO (2nd) (n=17,17) | 75.2 ± 13.6 | 83.3 ± 13.2 |
| Baseline 5 mins after NO administration (n=19,15) | 73.2 ± 10.2 | 84.3 ± 13.9 |
| Baseline 15 mins after NO administration(n=18,19) | 76.2 ± 9.0 | 85.1 ± 13.8 |
| Week 24 breathing ambient air (n=20,22) | 76.6 ± 8.6 | 83.0 ± 12.8 |
| Week 24 every 2 mins breathing NO (1st) (n=9,13) | 76.3 ± 10.1 | 82.5 ± 15.3 |
| Week 24 every 2 mins breathing NO (2nd) (n=8,11) | 76.6 ± 10.3 | 82.8 ± 16.7 |
| Week 24 5 mins after NO administration (n=9,12) | 75.7 ± 10.2 | 79.3 ± 10.4 |
| Week 24 15 mins after NO administration (n=10,14) | 73.2 ± 8.3 | 82.9 ± 10.5 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Cardiac Output (CO). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
| L/min | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=27,28) | 4.20 ± 1.33 | 4.09 ± 1.44 |
| Baseline every 2 mins breathing NO (1st) (n=19,20) | 4.02 ± 1.32 | 4.22 ± 1.64 |
| Baseline every 2 mins breathing NO (2nd) (n=17,18) | 3.98 ± 1.16 | 4.43 ± 1.80 |
| Baseline 5 mins after NO administration (n=19,14) | 4.20 ± 1.16 | 4.71 ± 1.95 |
| Baseline 15 mins after NO administration(n=18,19) | 3.87 ± 1.03 | 4.47 ± 2.15 |
| Week 24 breathing ambient air (n=20,22) | 4.90 ± 1.21 | 4.35 ± 1.57 |
| Week 24 every 2 mins breathing NO (1st) (n=10,13) | 4.80 ± 1.26 | 4.67 ± 2.27 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 4.79 ± 1.31 | 4.62 ± 2.26 |
| Week 24 5 mins after NO administration (n=10,12) | 4.63 ± 1.21 | 4.65 ± 1.99 |
| Week 24 15 mins after NO administration (n=10,14) | 4.48 ± 1.21 | 4.46 ± 1.98 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. PVR calculated according to the equation:PVR = (PAP - PCWP)/CO
| dyn*s/cm^5 | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=27,27) | 1124.4 ± 460.0 | 1118.3 ± 486.7 |
| Baseline every 2 mins breathing NO (1st) (n=19,17) | 1180.9 ± 520.8 | 1067.9 ± 509.1 |
| Baseline every 2 mins breathing NO (2nd) (n=17,16) | 1064.6 ± 458.9 | 982.8 ± 483.9 |
| Baseline 5 mins after NO administration (n=19,11) | 1131.5 ± 491.2 | 1160.4 ± 510.0 |
| Baseline 15 mins after NO administration(n=18,16) | 1181.9 ± 498.7 | 1132.9 ± 461.0 |
| Week 24 breathing ambient air (n=19,21) | 729.9 ± 230.1 | 1017.0 ± 369.1 |
| Week 24 every 2 mins breathing NO (1st) (n=9,14) | 706.9 ± 285.5 | 1000.6 ± 501.5 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 687.4 ± 276.3 | 1033.6 ± 546.2 |
| Week 24 5 mins after NO administration (n=10,12) | 717.2 ± 271.6 | 987.8 ± 370.4 |
| Week 24 15 mins after NO administration (n=10,14) | 776.1 ± 286.8 | 1042.5 ± 388.4 |
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systemic Vascular Resistance (SVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. SVR was calculated according to the equation: SVR = (Paorta - Pright atrium)/CO
| dyn*s/cm^5 | STI571 | Placebo |
|---|---|---|
| Baseline breathing ambient air (n=26,26) | 1674.4 ± 761.2 | 1764.8 ± 481.9 |
| Baseline every 2 mins breathing NO (1st) (n=18,15) | 1778.2 ± 709.5 | 1769.7 ± 457.0 |
| Baseline every 2 mins breathing NO (2nd) (n=16,14) | 1807.3 ± 615.1 | 1664.7 ± 472.0 |
| Baseline 5 mins after NO administration (n=18,11) | 1609.2 ± 593.4 | 1666.6 ± 488.6 |
| Baseline 15 mins after NO administration(n=17,15) | 1976.3 ± 877.5 | 1748.4 ± 499.3 |
| Week 24 breathing ambient air (n=18,21) | 1427.2 ± 446.8 | 1667.9 ± 357.8 |
| Week 24 every 2 mins breathing NO (1st) (n=9,13) | 1344.2 ± 474.8 | 1579.3 ± 386.8 |
| Week 24 every 2 mins breathing NO (2nd) (n=9,11) | 1367.9 ± 601.7 | 1592.5 ± 389.0 |
| Week 24 5 mins after NO administration (n=9,12) | 1419.7 ± 566.6 | 1503.9 ± 305.3 |
| Week 24 15 mins after NO administration (n=10,14) | 1431.7 ± 524.4 | 1629.3 ± 355.6 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaO2 levels at baseline and Study completion Week 24.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline n=22,21 | 63.36 ± 14.33 | 63.75 ± 12.02 |
| Week 24 n=16,17 | 72.49 ± 14.09 | 70.13 ± 16.72 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaCO2 levels at baseline and Study completion Week 24.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline n=23,21 | 32.70 ± 4.40 | 30.02 ± 4.76 |
| Week 24 n=16,17 | 33.36 ± 5.11 | 30.23 ± 3.55 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PvO2 levels at baseline and Study completion Week 24.
| mmHg | STI571 | Placebo |
|---|---|---|
| Baseline n=14,14 | 33.16 ± 4.62 | 34.70 ± 4.75 |
| Week 24 n=11,11 | 35.56 ± 3.80 | 32.65 ± 4.18 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Arterial Saturation levels at baseline and Study completion Week 24.
| percentage of saturation | STI571 | Placebo |
|---|---|---|
| Baseline n=19,16 | 87.99 ± 9.19 | 91.81 ± 4.05 |
| Week 24 n=14,15 | 92.89 ± 4.50 | 91.78 ± 3.36 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Venous Saturation levels at baseline and Study completion Week 24.
| percentage of saturation | STI571 | Placebo |
|---|---|---|
| Baseline n=17,14 | 57.96 ± 10.48 | 60.84 ± 6.61 |
| Week 24 n=13,13 | 65.11 ± 6.91 | 57.00 ± 9.18 |
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including pH levels at baseline and Study completion Week 24. The pH scale measures how acidic or basic a substance is. It ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic.
| pH scale | STI571 | Placebo |
|---|---|---|
| Baseline n=24,23 | 7.43 ± 0.04 | 7.44 ± 0.05 |
| Week 24 n=17,17 | 7.44 ± 0.05 | 7.46 ± 0.05 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core - STI571 | — | 12/28 (42.9%) | 26/28 (92.9%) |
| Core - Placebo | — | 11/31 (35.5%) | 25/31 (80.6%) |
| Extension - STI571 | — | 16/22 (72.7%) | 21/22 (95.5%) |
| Event | Core - STI571 | Core - Placebo | Extension - STI571 |
|---|---|---|---|
| Disease progressionGeneral disorders | 0/28 | 0/31 | 7/22 |
| SyncopeNervous system disorders | 2/28 | 1/31 | 3/22 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/28 | 3/31 | 1/22 |
| Cardiac failureCardiac disorders | 0/28 | 0/31 | 2/22 |
| Lung infectionInfections and infestations | 0/28 | 0/31 | 2/22 |
| Cardiac arrestCardiac disorders | 2/28 | 2/31 | 0/22 |
| PresyncopeNervous system disorders | 2/28 | 1/31 | 1/22 |
| Right ventricular failureCardiac disorders | 1/28 | 2/31 | 1/22 |
| Fluid retentionMetabolism and nutrition disorders | 0/28 | 2/31 | 1/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/28 | 2/31 | 1/22 |
| Event | Core - STI571 | Core - Placebo | Extension - STI571 |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/28 | 8/31 | 14/22 |
| NauseaGastrointestinal disorders | 14/28 | 5/31 | 8/22 |
| Respiratory tract infectionInfections and infestations | 6/28 | 1/31 | 11/22 |
| DiarrhoeaGastrointestinal disorders | 6/28 | 3/31 | 9/22 |
| Oedema peripheralGeneral disorders | 7/28 | 5/31 | 9/22 |
| VertigoEar and labyrinth disorders | 4/28 | 4/31 | 8/22 |
| OedemaGeneral disorders | 1/28 | 0/31 | 8/22 |
| HeadacheNervous system disorders | 10/28 | 6/31 | 4/22 |
| Urinary tract infectionInfections and infestations | 0/28 | 0/31 | 7/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/28 | 6/31 | 7/22 |
| Age, Continuous(years) | STI571 | Placebo | Total |
|---|---|---|---|
| Mean | 44.4 ± 15.3 | 44.2 ± 15.7 | 44.3 ± 15.4 |
| Sex: Female, Male(Participants) | STI571 | Placebo | Total |
|---|---|---|---|
| Female | 18 | 22 | 40 |
| Male | 10 | 9 | 19 |
The record gives a start of Apr 2006, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Pulmonary Arterial Hypertension →